DUBLIN, April 12, 2021 /PRNewswire/ -- Cosmo Pharmaceuticals NV (SIX: COPN) today announced the FDA approval of GI Genius™ intelligent endoscopy system, its revolutionary device for lesion detection ...

Please provide your email address to receive an email when new articles are posted on . Medtronic recently received FDA de novo clearance for the GI Genius intelligence endoscopy module. GI Genius is ...

Dublin, Ireland--(Newsfile Corp. - June 24, 2025) - Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced that in July 2025, it will initiate their first usability study of a medical device software ...

The GI Genius™ Intelligent Endoscopy Module Helps Transform Colorectal Cancer Detection in New York NEW YORK, August 17, 2023--(BUSINESS WIRE)--Kips Bay Endoscopy Center (KBEC), a Covenant Physician ...

The GI Genius module uses advanced artificial intelligence to highlight the presence of pre-cancerous lesions with a visual marker in real-time – serving as an ever vigilant second observer. Studies ...

Colorectal cancer — more widely known as colon cancer — is the second-most-common cause of cancer deaths in the US. 5 But if you catch it early, the chance for survival can be as high as 90%. 6 To ...

Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Dublin, Ireland - 12 April 2021: Cosmo Pharmaceuticals NV (SIX: COPN) ...

NEW YORK--(BUSINESS WIRE)--Kips Bay Endoscopy Center (KBEC), a Covenant Physician Partner, will offer patients receiving a colonoscopy an enhanced screening with the aid of GI Genius™ intelligent ...

Cosmo Pharmaceuticals NV (SIX: COPN) today announced the FDA approval of GI Genius(TM) intelligent endoscopy system, its revolutionary device for lesion detection during colonoscopy. The GI Genius ...

The GI Genius module FDA approval marks a pivotal milestone for Cosmo after more than 10 years of research and investments focused to generate disruptive innovations in the field of colon's disease ...